Immunosuppressants for therapy of patients with ulcerative colitis

Tadakazu Hisamatsu, Toshifumi Hibi

研究成果: Review article査読

抄録

Ulcerative colitis (UC) has been known as inflammatory bowel disease. Progress in UC management strategies has led to optimized approaches for achieving the two primary clinical goals of therapy: induction and maintenance of remission. We here review about immunosuppressants in management of UC; Cyclosporine A (CsA) has been used for the induction therapy in steroid resistant refractory UC. Although it has been reported that CsA has high response rate in severe UC, long-term efficacy (maintenance of remission) has not been proven. To improve maintenance therapy, immunosuppressant has been re-considered in management of UC. In recent years, it has been reported that efficacy of 6-mercaptopurine/azathioprine in maintenance of remission of UC is superior to 5-aminosalicylate (5-ASA). Pharmacological studies have indicated thiopurine methyltransferase (TPMT) activity is essential for maintenance of blood concentration of 6-thioguanine nucleotide (6-TG).

本文言語English
ページ(範囲)831-835
ページ数5
ジャーナルNippon rinsho. Japanese journal of clinical medicine
63
5
出版ステータスPublished - 2005 5

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「Immunosuppressants for therapy of patients with ulcerative colitis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル